43189-38-4Relevant academic research and scientific papers
Shape-Persistent Actuators from Hydrazone Photoswitches
Ryabchun, Alexander,Li, Quan,Lancia, Federico,Aprahamian, Ivan,Katsonis, Nathalie
, p. 1196 - 1200 (2019)
Interfacing molecular photoswitches with liquid crystal polymers enables the amplification of their nanoscale motion into macroscopic shape transformations. Typically, the mechanism responsible for actuation involves light-induced molecular disorder. Here, we demonstrate that bistable hydrazones can drive (chiral) shape transformations in liquid crystal polymer networks, with photogenerated polymer shapes displaying a long-term stability that mirrors that of the switches. The mechanism involves a photoinduced buildup of tension in the polymer, with a negligible influence on the liquid crystalline order. Hydrazone-doped liquid crystal systems thus diversify the toolbox available to the field of light-adaptive molecular actuators and hold promise in terms of soft robotics.
Development and large-scale preparation of an oral TACE inhibitor
Savage, Scott A.,Waltermire, Robert E.,Campagna, Silvio,Bordawekar, Shailendra,Toma, Joan Dalla Riva
experimental part, p. 510 - 518 (2010/04/22)
An efficient, expedient synthesis of BMS-561392, 1, which enabled rapid delivery of drug substance for clinical development is described. The key features of the synthesis include an efficient synthesis of a phenolic α,α-disubstituted amino ester via carbon alkylation without protection of the phenol, an effective enzymatic resolution of this racemic amino ester, and a process for the preparation of a hydroxamic acid drug substance with undetectable levels of hydroxylamine.
Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone
-
Page/Page column 15, (2010/11/30)
A novel process for the asymmetric synthesis of an amino-pyrrolidinone of the type shown below is described. These compounds are useful as intermediates for MMP and TACE inhibitors. Crystalline, free-base form of Compound J ((2R)-2-((3R)-3-amino-3-{-[(2-m
DPC 333 formulation having unique biopharmaceutical characteristics
-
Page 7, (2010/02/06)
Oral dosage forms of the crystalline, free base of ([1-(R)]-3-amino-N-hydroxy-alpha-(2-methylpropyl)-3-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]-2-oxo-1-pyrrolidineacetamide, referred to herein as DPC 333, having unique biopharmaceutical characteristics
